Clinical Trials vs FDA Actions
Side-by-side coverage analysis for Clinical Trials and FDA Actions.
Clinical Trials
Phase I-III results, trial design
- Stories
- 20
- Avg Impact
- 6.8/10
- Dominant Tone
- Bullish
- Latest
- Mar 25, 2026
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 0
- Avg Impact
- 0/10
- Dominant Tone
- Very Bullish
Recent Headlines
Clinical Trials
- Hope Medicine Doses First Patient in Phase III Trial for Endometriosis Therapy
- Pfizer's Lyme Vaccine Shows Over 70% Efficacy in Pivotal Phase 3 Trial
- Hope Medicine Doses First Patient in Phase III Endometriosis Trial for HMI-115
- Innovent's IBI302 Hits Phase 3 Goal, Pioneering Extended nAMD Care in China
- Monash University and ClinChoice Partner to Accelerate Clinical Development
- First Lab-Grown Oesophagus Breakthrough Offers Hope for Rare Pediatric Conditions
- iBio Targets Q3 for Lead Bispecific Candidate in PH-HFpEF Treatment
- RBC Capital Backs Eli Lilly’s Retatrutide as Next-Gen Obesity Powerhouse
- Curis Completes Strategic Pivot to Oncology Pipeline Following Erivedge Sale
- Acumen Pharmaceuticals Targets 2026 Milestone for Alzheimer’s Antibody
FDA Actions
No recent stories found.